ArticleEmerging infectious diseases2026
Predictors of Fatal Outcomes among Pediatric Patients Hospitalized for Rocky Mountain Spotted Fever, Sonora, Mexico, 2004-2024
Article in Emerging infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Geographic Variation in the Bacterial Microbiota ofBiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tickborne disease Rocky Mountain spotted fever (RMSF) remains life-threatening among children in northern Mexico. We retrospectively investigated 500 pediatric RMSF patients hospitalized in Sonora during 2004-2024. We analyzed clinical, laboratory, and sociodemographic data to identify predictors of fatality by using descriptive statistics and multivariable logistic regression. We found that the overall case-fatality rate was 19.8%, decreasing over time from 31.4% (2004-2013) to 14.5% (2014-2024). Fatal outcomes were associated with delayed doxycycline treatment (>5 days after symptom onset), older age, Indigenous background, and abnormal laboratory markers. Among survivors, 16% had life-altering sequelae, including amputations and neurologic deficits. Cases occurred year-round, predominantly in urban settings. Timely doxycycline administration remains a critical factor in reducing mortality rates. Vulnerable populations, including persons living in poverty, children >10 years of age, and Indigenous communities, require targeted interventions. Strengthening early diagnosis and understanding mechanisms underlying severe disease and death could improve RMSF outcomes in endemic regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.